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To the Editor:
We read with interest the study by Lertsbur-
apa and colleagues1 highlighting the benefi-
cial effects of preoperative statin therapy on
atrial fibrillation (AF) after cardiac surgery.
This nested cohort analysis constituted part
of the Atrial Fibrillation Suppression Trials
I, II, and III, which evaluated the effects of
oral amiodarone, atrial septal pacing and
preservation of aortic fat pad on AF after
cardiac surgery. A total of 555 patients
were studied. Postoperative AF occurred in
27.8%of the patients receiving statins versus.
36.6% not receiving statins, demonstrating
a statistically significant reduction in postop-
erative AF in response to statin therapy.
In an attempt to correct for the confound-
ing effects of such variables as age, preoper-
ative AF, and valve surgery, Lertsburapa
and colleagues1 performed a stepwise multi-
variate regression analysis, which con-
firmed the beneficial impact of statin
treatment on postoperative AF. However,
it is well-established that in nonrandomised
comparative studies, multivariate analysis
alone may not be sufficient to adjust for
treatment-selection bias and other balancing
methods will have to be employed.2
Lertsburapa and colleagues1 suggest
a dose-dependent effect of statins on postop-
erative AF. Atorvastatin$40 mg or equiva-
lent doses conferred the greatest effect when
compared with no statins. Atorvastatin$20
mg but ,40 mg, and ,20 mg equivalents
also conferred an incremental reduction in
AF, albeit not statistically significant. Statin
types were converted into atorvastatin
equivalents based on their lipid-lowering
properties as previously evaluated by effi-
cacy comparison trials.3 The division of
statin doses to high, intermediate and low
is conventionally based on their lipid-lower-
ing efficacy, but it is now well-established
that statins exhibit ‘pleiotropic’ properties.
Lertsburapa and colleagues have used this
arbitrary division by creating dose-equiva-iovascular Surgery c October 2008lents, which may have influenced the accu-
racy of their results.
Our group has recently examined the
effect of varying doses of statins on postop-
erative AF in 623 patients undergoing car-
diac surgery.4 We concur with Lertsburapa
and colleagues that statins significantly re-
duce AF and that this effect is dose-related.
However, following propensity score analy-
sis, we identified that the antifibrillatory
effect of statins did not match their lipid-
lowering capacity. More specifically, sim-
vastatin 20 mg, which is an atorvastatin
10 mg equivalent based on lipid-lowering
efficacy, demonstrated a statistically signif-
icant effect on postoperative AF when
compared to no statins (OR 2.32, 95%CI
1.30-4.11), whereas atorvastatin 10 mg had
no impact on AF (OR 1.05, 95%CI 0.55-
1.99). In addition, the beneficial effect of
simvastatin 40 mg (OR 3.89, 95%CI 2.03-
7.45), which is an atorvastatin 20 mg equiv-
alent, was significantly more pronounced
than the effect conferred by atorvastatin
20 mg (OR 1.99, 95%CI 1.00-3.94) or ator-
vastatin 40 mg (OR 2.76, 95%CI 1.24-6.15)
when compared to no statins.
In conclusion, there is enough evidence
to support the antiarrhythmic role of statins
through mechanisms independent of their
lipid-lowering activity, such as modulation
of inflammatory response and atrial struc-
tural remodeling.5 However, we suggest
that since there is an indication of differen-
tial effect of equivalent statin doses, appro-
priate methodological measures need to be
in place when assessing outcomes beyond
their lipid-lowering capacity.
Antonios Kourliouros, MRCS
Neil Roberts, MRCS
Marjan Jahangiri, FRCS
Department of Cardiothoracic Surgery
St George’s Hospital
London, UK
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Preoperative statins for the prevention of atrial
tion. We would have liked to evaluate
different statins and doses independently;
however, the relatively small number of
patients receiving a statin and the heteroge-
neous uses of different statins and doses
by patients enrolled in the cohort would
have resulted in an underpowered analysis.1
That being said, we applaud the work of
Kourliouros, Roberts, and Jahangiri in con-
ducting an additional analysis to further the
research in this area.3 Ultimately, as Kour-
liouros, Roberts, and Jahangiri suggest, all
nonrandomized studies likely suffer from
some degree of bias or confounding, which
is why a randomized, controlled trial will be
needed to determine definitively whether
different statins exhibit different abilities to
prevent post-CTS atrial fibrillation and
whether dose-response relationships do, in
them had valve operations, which is a signif-
icant confounder for occurrence of postop-
erative atrial arrhythmias. Analysis of the
lone Cox maze IV group would probably of-
fer better insight into the benefit of the box
lesion. However, the numbers seem to be
so small that there may not be adequate
power for this analysis. I will look forward
to any follow-up data in the future from
the authors.
Uma N. Srivatsa, MD
Internal Medicine/Cardiology
University of California—Davis
Sacramento, CA 95670
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My coauthors and I thank Drs Kourliouros,
Roberts, and Jahangiri for their interest in
our recent study.1 We do not disagree with
their suggestion that different statins may
exhibit varying degrees of pleiotropic
effects (eg, anti-inflammatory effects), and
thus believe that their hypothesis that statins
may have differential abilities to prevent
postcardiothoracic surgery (CTS) atrial fi-
brillation is not unreasonable. It is, however,
important to note that the intent of our
nested cohort study was to assess whether
statins as a class are associated with reduc-
tions in post-CTS atrial fibrillation when
used in patients who already have a high
background use of b-blockers (84%) and
appreciable use of prophylactic amiodarone
(44%), rather than to evaluate individual
statins or a dose-response relationship.1
Our primary analysis was worthwhile,
because a large proportion of patients in
ARMYDA-3—the only randomized con-
trolled trial designed to assess the effect of
a statin (atorvastatin at 40 mg/d) on post-
CTS atrial fibrillation as a primary end
point—did not receive b-blockers (arguably
the criterion standard preventative strategy),
and virtually none received prophylactic
amiodarone.2 This treatment pattern likely
explains the high incidence of post-CTS
atrial fibrillation (57%) seen in the AR-
MYDA-3 control group.
Despite the criticism by Kourliouros,
Roberts, and Jahangiri of our dose-response
analysis, we believe that it provides valuable
data to support the claim of a dose-response
effect of statins on post-CTS atrial fibrilla-
fact, exist.
Craig Ian Coleman, PharmD
University of Connecticut School of Pharmacy
Storrs, Conn
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Box lesion or not—Still
unsettled question
To the Editor:
I read with interest the article by Voeller and
associates1 in the April 2008 issue of the
Journal. This is a single center study look-
ing at occurrences of atrial arrhythmias on
follow-up in patients who had the Cox
maze IV procedure with and without box le-
sions. Although the authors have acknowl-
edged several limitations, I would like to
point out another important limitation.
Over 60% of the patients had concomitant
procedures, and a significant proportion of
entire posterior left atrium improves surgical
outcomes after the Cox maze procedure.
J Thorac Cardiovasc Surg. 2008;135:870-7.
doi:10.1016/j.jtcvs.2008.04.028
Aortic valve replacement
dilemma: mechanical or
biological prosthesis?
To the Editor:
The selection of the appropriate prosthesis
for aortic valve replacement (AVR) is still
open to debate in the case of patients in
the sixth and seventh decades of life.
Recently Brown and colleagues,1 from
Mayo Clinic, reported in the Journal on
an interesting retrospective study about
this topic. By means of patient matching
according to clinical features, they ob-
served in their population a survival advan-
tage after aortic valve replacement with
a mechanical prosthesis relative to a bio-
prosthesis. Brown and colleagues1 stated
that the study was subject to selection
bias and noted that despite case matching
and statistical analysis, surgical bias cannot
be eliminated. Also, in our opinion, it is
virtually impossible to avoid at all biases
and confounding factors in clinical studies.
Nevertheless, the recording of aortic valve
replacement as associated or not with coro-
nary artery bypass grafting simply as a bi-
nary variable could be quite misleading in
drawing conclusions from data analysis.
In fact, age being equal, surgeons could
elect to implant a bioprosthesis rather
than a mechanical valve in patients affected
by more severe coronary artery disease.
Both the extent—isolated single-vessel dis-
ease versus triple-vessel disease—and the
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